

## **Product datasheet for TL306734**

JAML Human shRNA Plasmid Kit (Locus ID 120425)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** JAML Human shRNA Plasmid Kit (Locus ID 120425)

**Locus ID:** 120425

Synonyms: AMICA; AMICA1; CREA7-1; CREA7-4; Gm638

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** JAML - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 120425).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001098526, NM 001286570, NM 001286571, NM 153206, NR 104479, NM 001098526.1,

NM 153206.1, NM 153206.2, NM 001286570.1, NM 001286571.1, BC100794, BC100795, BC100796, BC100797, NM 001286570.2, NM 001098526.2, NM 001286571.2, NM 153206.3

UniProt ID: Q86YT9

**Summary:** Transmembrane protein of the plasma membrane of leukocytes that control their migration

and activation through interaction with CXADR, a plasma membrane receptor found on adjacent epithelial and endothelial cells. The interaction between both receptors mediates the activation of gamma-delta T-cells, a subpopulation of T-cells residing in epithelia and involved in tissue homeostasis and repair. Upon epithelial CXADR-binding, JAML induces downstream cell signaling events in gamma-delta T-cells through PI3-kinase and MAP kinases. It results in proliferation and production of cytokines and growth factors by T-cells that in turn stimulate epithelial tissues repair. It also controls the transmigration of leukocytes within

epithelial and endothelial tissues through adhesive interactions with epithelial and

endothelial CXADR.[UniProtKB/Swiss-Prot Function]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).